Does Rallies show Form 4 insider transactions for PHAT?

Yes. Rallies tracks PHAT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PHAT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PHAT. It does not provide personalized investment advice.

PHAT (Phathom Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Phathom Pharmaceuticals, Inc. Common Stock (PHAT) is a publicly traded Healthcare sector company. As of May 20, 2026, PHAT trades at $11.51 with a market cap of $908.42M and a P/E ratio of -3.77. PHAT moved +0.35% today. Year to date, PHAT is -27.43%; over the trailing twelve months it is +159.68%. Its 52-week range spans $2.21 to $19.50. Analyst consensus is strong buy with an average price target of $24.25. Rallies surfaces PHAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PHAT stock inside the company?

Recent PHAT insider activity includes Breedlove Robert Charles sold 524, Breedlove Robert Charles sold 461, Breedlove Robert Charles sold 1.69K, Topper James N bought 3.78K, and Topper James N bought 6.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PHAT Key Metrics

Key financial metrics for PHAT
Metric	Value
Price	$11.51
Market Cap	$908.42M
P/E Ratio	-3.77
EPS	$-3.03
Dividend Yield	0.00%
52-Week High	$19.50
52-Week Low	$2.21
Volume	186.89K
Avg Volume	0
Revenue (TTM)	$175.11M
Net Income	$-221.25M
Gross Margin	87.09%

Recent PHAT Insider Trades

Breedlove Robert Charles sold 524 (~$7.08K) on Nov 3, 2025.
Breedlove Robert Charles sold 461 (~$5.57K) on Sep 5, 2025.
Breedlove Robert Charles sold 1.69K (~$14.15K) on Jul 16, 2025.
Topper James N bought 3.78K (~$14.61K) on May 21, 2025.
Topper James N bought 6.30K (~$20.92K) on May 14, 2025.

Latest PHAT News

Phathom Presents 31 Vonoprazan Abstracts, Phase 3 Analysis Earns Poster Distinction — May 20, 2026
Phathom to Host VOQUEZNA Theater and 3 Posters at DDW 2026 — May 1, 2026
Phathom Reports 104% Revenue Growth to $58.3M and Cuts Costs 43% — Apr 30, 2026
Phathom Aims for H2 2026 Profitability After $175M 2025 Revenue and GI Focus — Feb 14, 2026
Phathom Prices $130M Offering of 6.875M Shares and 1.25M Warrants — Jan 8, 2026

PHAT Analyst Consensus

6 analysts cover PHAT: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.25.

Common questions about PHAT

Who is trading PHAT stock inside the company?: Recent PHAT insider activity includes Breedlove Robert Charles sold 524, Breedlove Robert Charles sold 461, Breedlove Robert Charles sold 1.69K, Topper James N bought 3.78K, and Topper James N bought 6.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PHAT?: Yes. Rallies tracks PHAT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PHAT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PHAT. It does not provide personalized investment advice.